Canakinumab in the treatment of tumour necrosis factor receptor-associated periodic syndrome (TRAPS) - European Medical Journal

Canakinumab in the treatment of tumour necrosis factor receptor-associated periodic syndrome (TRAPS)

Oncology

At the American College of Rheumatology Annual Meeting, which took place in San Francisco, California, USA, from 6 to 11 November 2015, Helen Lachmann, MA, MB BChir, MD, FRCP, from the Royal Free London NHS Foundation Trust, London, UK discusses the results of a trial which analysed the use of canakinumab to treat tumour necrosis factor receptor-associated periodic syndrome (TRAPS), and how they relate to her own experiences in the UK.

Please rate the quality of this content

As you found this content interesting...

Follow us on social media!

We are sorry that this content was not interesting for you!

Let us improve this content!

Tell us how we can improve this content?

Keep your finger on the pulse

Join Now

Elevating the Quality of Healthcare Globally

>